(Q38116070)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Proteins: emerging carrier for delivery of cancer therapeutics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ambikanandan Misra

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Chetan Yewale

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Dipesh Baradia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

22 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Delivery

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

1429-1448

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Antibody-enzyme fusion proteins for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

TIMP-2 fusion protein with human serum albumin potentiates anti-angiogenesis-mediated inhibition of tumor growth by suppressing MMP-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Transferrin receptors in human tissues: their distribution and possible clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Transferrin receptor on endothelium of brain capillaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Killing of human tumor cells in culture with adriamycin conjugates of human transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Characterization of the anti-cancer activity of transferrin-adriamycin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Transferrin-antibody fusion proteins are effective in brain targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Changing views of the role of matrix metalloproteinases in metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Controlled release of plasmid DNA from hydrogels prepared from gelatin cationized by different amine compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Nanoparticle and targeted systems for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Poly-L-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Preparation and characterization of thermo-responsive albumin nanospheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Targeting of albumin-embedded paclitaxel nanoparticles to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Effects of artemisinin-tagged holotransferrin on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Biological activity of a gallic acid-gelatin conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Formulating paclitaxel in nanoparticles alters its disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Drug delivery to solid tumors by elastin-like polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.805200

10.1517/17425247.2013.805200

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23789923%20AND%20SRC:MED&resulttype=core&format=json

release_6fffim22ong6znnwhxnk7lnnzq

3 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6fffim22ong6znnwhxnk7lnnzq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference